JF
IMDX

Jump Financial’s Insight Molecular Diagnostics IMDX Stock Holding History

Jump Financial’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,457
Closed -$26K – 1840
2022
Q2 		$26K Buy
+1,457
New +$33.1K ﹤0.01% 1531
2022
Q1 		– Sell
-3,685
Closed -$160K – 1797
2021
Q4 		$160K Buy
3,685
+2,850
+341% +$164K 0.01% 1155
2021
Q3 		$59K Sell
835
-8
-0.9% -$735 ﹤0.01% 1020
2021
Q2 		$97K Buy
+843
New +$82.3K 0.01% 982

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Jump Financial's IMDX Position: Q3 2022 in Review

Jump Financial sold out of Insight Molecular Diagnostics (IMDX) in Q3 2022, closing a stake of 1,457 shares — an estimated $26K sold.

Jump Financial first reported a position in IMDX in Q2 2021 and held it in 4 quarters. The position peaked at $160K in Q4 2021. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

  • Jump Financial reported no remaining Insight Molecular Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Jump Financial sold 1,457 Insight Molecular Diagnostics shares in Q3 2022, an estimated $26K.
  • Jump Financial first reported a position in Insight Molecular Diagnostics in Q2 2021 and held it in 4 quarters.
  • Jump Financial's Insight Molecular Diagnostics position peaked at $160K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on Jump Financial's 13F filing for Q3 2022, filed 7 Nov 2022.